Retrogenix’s novel cell microarray technology is the world leading solution for off-target screening and primary receptor identification, providing key data for lead selection and regulatory applications.

Our unique platform assesses binding of test molecules against a comprehensive library of 6,200+ human plasma membrane proteins, secreted proteins, and heterodimeric plasma membrane protein complexes, all expressed in human cells.

Retrogenix works with all of the top 20 pharmaceutical companies, including Novartis and Takeda, many biotechnology companies worldwide, and leading research institutions, to accelerate and de-risk their drug discovery programs. Our technology is widely published in high impact journals, such as Nature, Molecular Cancer, Cancer Cell, mBio and Oncotarget.

Retrogenix has been used in many successful IND and BLA submissions worldwide. The data can replace tissue cross-reactivity studies, and are accepted by FDA, EMA, NMPA, and PMDA.

Learn more about Retrogenix data in regulatory submissions.

Retrogenix studies have:

  • High success rates
  • Very low incidence of false positives
  • Rapid turnaround times
  • High degree of sensitivity and specificity, even for low affinity interactions

Types of molecules screened:

  • Antibodies
  • CAR-T Cells
  • scFv’s
  • Peptides
  • Proteins, ADCs
  • Small Molecules
  • Viruses

In 2015, Retrogenix won the Queen’s Award for Enterprise – the UK’s most prestigious business accolade – in recognition of its innovative work in developing and commercialising the cell microarray technology. This was followed in 2017 by a second Queen’s Award for outstanding achievements in international trade.

Members of our team are regularly invited to present at international events, and we frequently attend conferences, such as BioJapan.

Retrogenix is headquartered in the High Peak, UK, and all project work is undertaken by highly skilled scientists in our specialist laboratory facilities on-site in the UK. The company also has offices in Cambridge, MA, and Tsukuba, Japan. Retrogenix continues to build on its global reputation and the team continues to rapidly expanding to keep pace with demand for its services.

To find out more about study types, timelines, and costs, please get in touch.

Find out more:

Connect with us:

T. +(0)441663 732520
E. info@retrogenix.com

 

 

Retrogenix Limited

High Peak Business Park, Buxton Road
Chinley, High Peak
SK23 6FJ
UK

Retrogenix Limited (China)

High Peak Business Park, Buxton Road
Chinley, High Peak
SK23 6FJ
UK

Get In Touch

    Simcere logo
    Aveo Oncology - The Human Response
    Theraclone Sciences
    BioInvent
    AstraZeneca
    Bluebird Bio
    glycotope_logo
    The Center for Infectious Disease Research
    Compugen Logo
    Sanofi Logo
    The University of Copenhagen
    Lund University
    MedImmune
    NIH - National Institutes of Health
    The University of Pennsylvania
    Scripps Florida - The Scripps Research Institute
    Peptinnovate Ltd - Unlocking Nature's Potential
    The University of Sheffield
    Capella Bioscience Logo
    Unum Theraputics Logo
    Celyad Logo

    Testimonials

    Find out what our customers say:

    Retrogenix have been an excellent partner for us, and done high-quality studies. They have a collaborative approach and the flexibility to design studies to ensure the best possible outcomes.
    Dr. David King, SVP Research, aTyr Pharma